Every material Form 8-K United Therapeutics filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
United Therapeutics reported record third-quarter 2025 results, with total revenues up 7% year over year to $799.5 million and net income up 10% to $338.7 million. Diluted earnings per share rose 12% to $7.16, and the company said Tyvaso DPI growth drove the increase.
Total revenues of $799.5 million for the quarter ended September 30, 2025, compared with $748.9 million a year earlier.
Diluted earnings per share of $7.16, compared with $6.39 in the third quarter of 2024, up 12%.
Tyvaso DPI net product sales rose 22% to $336.2 million, while Nebulized Tyvaso sales fell 11% to $141.8 million.
On August 1, 2025, United Therapeutics entered two accelerated share repurchase agreements with Citibank, N.A., totaling $1 billion under the $1 billion program its board approved on July 30, 2025. The company makes the full $1 billion upfront payment to Citi on August 4, 2025, and receives initial share deliveries that day, with the final number of shares repurchased to be set by future average prices. For shareholders, the buyback is a large use of company cash, and the filing does not yet state the total number of shares that will be repurchased.
Two agreements of $500 million each: an uncollared ASR and a collared ASR with Citi.
Aggregate upfront payment of $1 billion to Citi due August 4, 2025.
Initial deliveries on August 4, 2025 of about 1,274,296 shares (uncollared) and about 849,531 shares (collared).
Final settlement expected in the fourth quarter of 2025 (uncollared) and the first quarter of 2026 (collared).
United Therapeutics reported record second quarter 2025 total revenue of $798.6 million, up 12 percent from $714.9 million a year earlier, and net income of $309.5 million, up 11 percent. Diluted EPS rose 10 percent to $6.41, and the Board authorized share repurchases of up to $1 billion expiring March 31, 2026.
Total revenue $798.6 million vs. $714.9 million in Q2 2024, up 12 percent
Tyvaso DPI revenue $315.2 million, up 22 percent; Nebulized Tyvaso $154.4 million, up 10 percent
Net income $309.5 million vs. $278.1 million; diluted EPS $6.41 vs. $5.85
Share repurchase authorization of up to $1 billion, expiring March 31, 2026; $21.7 million PP&E impairment recorded
United Therapeutics reported first quarter 2025 results for the quarter ended March 31, 2025, with total revenues up 17% year over year to $794.4 million. Net income rose 5% to $322.2 million, and diluted earnings per share rose 7% to $6.63, though research and development expense grew 43% to $149.0 million.
Total Tyvaso revenues rose 25% to $466.3 million, led by Tyvaso DPI at $302.5 million, up 33%.
Net income was $322.2 million versus $306.6 million a year earlier; diluted EPS was $6.63 versus $6.17.
Research and development expense rose to $149.0 million from $104.1 million, including a $30.0 million increase in milestone payments for drug delivery device technologies.
The filing contains no revenue or earnings guidance; the company said it would host a webcast on April 30, 2025 at 9:00 a.m. Eastern Time.
On April 25, 2025, United Therapeutics entered a five-year unsecured revolving credit agreement with Wells Fargo as administrative agent, providing up to $2.5 billion, with an option to increase it by up to $750 million. The company borrowed $200.0 million at closing and used the funds to pay off and terminate its 2022 credit agreement with no early termination penalties. The filing shows a refinancing of existing debt rather than a change in operating results, and the new facility includes leverage and interest coverage covenants and a change-of-control default.
Unsecured revolving credit facility of up to $2.5 billion, maturing five years after closing, with up to two one-year extensions
Borrowed $200.0 million at closing on April 25, 2025, and used the proceeds to repay the 2022 Credit Agreement
2022 Credit Agreement, dated March 31, 2022, paid off and terminated with no early termination penalties
Covenants require total indebtedness to EBITDA of no more than 3.50 to 1.00 and interest coverage of at least 3.00 to 1.00
United Therapeutics reported fourth quarter and full year 2024 results on February 26, 2025. Revenue for the quarter rose 20% to $735.9 million and net income rose to $301.3 million, while full year revenue reached a record $2.88 billion, up 24%. Higher earnings for both periods point to strong sales of its treprostinil products for shareholders, though the company also booked a $71.1 million litigation accrual tied to Sandoz Inc. for 2024.
Q4 2024 diluted EPS was $6.19, compared with $4.36 in Q4 2023.
Full year 2024 net income was $1,195.1 million, compared with $984.8 million in 2023.
Total Tyvaso revenue grew 19% to $415.9 million in Q4 2024.
A $71.1 million accrual related to ongoing litigation with Sandoz Inc. was recorded as of December 31, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every United Therapeutics filing is on SEC EDGAR ↗. 8-K briefs of other companies →